Behcet's disease:: Ocular effects and treatment

被引:156
作者
Deuter, Christoph M. E. [1 ]
Koetter, Ina [2 ]
Wallace, Graham R. [3 ]
Murray, Philip I. [3 ]
Stuebiger, Nicole [1 ]
Zierhut, Manfred [1 ]
机构
[1] Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Dept Internal Med 2, D-72076 Tubingen, Germany
[3] Univ Birmingham, Acad Unit Ophthalmol, Div Immun & Infect, Birmingham, W Midlands, England
关键词
D O I
10.1016/j.preteyeres.2007.09.002
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Behcet's disease (1313) is a systemic immune-mediated vasculitis of unclear origin. Major symptoms include oral aphthous ulcers, genital ulcerations, skin lesions, and ocular lesions. Eye involvement, which affects 60-80% of BD patients, is characterized by posterior or panuveitis with occlusive retinal vasculitis. The pathogenesis of BD remains unclear, but research of the last decades has shown a complex role of genetic factors (HLA-B51) predisposing to inflammation with involvement of the innate-immune system (neutrophils, NK cells), perpetuated by the adaptive immune response, most importantly T cells, against infectious- and/or autoantigens. Despite aggressive immunosuppressive treatment, the visual prognosis of ocular BD was generally poor to date. Recently, novel biologic drugs, including interferon-alpha and tumour necrosis factor (TNF)-alpha-antagonists have been introduced in the treatment of ocular BD with very promising results and seem for the first time to improve the prognosis of the disease. This article will provide a current review of BD including recent developments in epidemiology, immunology, genetics, and treatment. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:111 / 136
页数:26
相关论文
共 240 条
[1]   Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease [J].
Abu El-Asrar A.M. ;
Abboud E.B. ;
Aldibhi H. ;
Al-Arfaj A. .
International Ophthalmology, 2005, 26 (3) :83-92
[2]   Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet's disease [J].
Adler, YD ;
Mansmann, U ;
Zouboulis, CC .
DERMATOLOGY, 2001, 203 (04) :322-324
[3]   Mapping the HLA association in Behcet's disease - A role for tumor necrosis factor polymorphisms? [J].
Ahmad, T ;
Wallace, GR ;
James, T ;
Neville, M ;
Bunce, M ;
Mulcahy-Hawes, K ;
Armuzzi, A ;
Crawshaw, J ;
Fortune, F ;
Walton, R ;
Stanford, MR ;
Welsh, KI ;
Marshall, SE ;
Jewell, DP .
ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :807-813
[4]   CD8 bright CD56+ T cells are cytotoxic effectors in patients with active Behcet's uveitis [J].
Ahn, JK ;
Chung, H ;
Lee, DS ;
Yu, YS ;
Yu, HG .
JOURNAL OF IMMUNOLOGY, 2005, 175 (09) :6133-6142
[5]  
Akdeniz N, 2004, ANN ACAD MED SINGAP, V33, P596
[6]   Serum substance P and calcitonin gene-related peptide levels in Behcet's disease and their association with disease activity [J].
Aki, T ;
Karincaoglu, Y ;
Seyhan, M ;
Batcioglu, K .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2006, 31 (04) :583-587
[7]   TNF-α gene 1031 T/C polymorphism in Turkish patients with Behcet's disease [J].
Akman, A. ;
Sallakci, N. ;
Coskun, M. ;
Bacanli, A. ;
Yavuzer, U. ;
Alpsoy, E. ;
Yegin, O. .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (02) :350-356
[8]   Clinical patterns of neurological involvement in Behcet's disease:: evaluation of 200 patients [J].
Akman-Demir, G ;
Serdaroglu, P ;
Tasçi, B .
BRAIN, 1999, 122 :2171-2181
[9]  
Allanore Y, 2004, CLIN EXP RHEUMATOL, V22, P756
[10]  
Altenburg Andreas, 2006, J Dtsch Dermatol Ges, V4, P49, DOI 10.1111/j.1610-0387.2006.05841.x